NY-HANSHOW
16.1.2023 15:01:38 CET | Business Wire | Press release
Hanshow participated in the 2023 National Retail Federation (NRF), the largest retail event in the world. At this year’s NRF Exhibition Booth, Hanshow unveiled a new generation protocol high-density low-power cellular network (HiLPC) and four-color Electronic Shelf Label (ESL). Hanshow has strengthened the operability of both its hardware and software and now provides more advanced solutions and services for the digital upgrading of retail industry customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005732/en/
Hanshow's new generation protocol high-density low-power cellular network (HiLPC) (Graphic: Business Wire)
Rapid upgrading that is more than just “fast”
Hanshow already provided the world’s leading series of ESL products, and this advanced performance has been further improved through Hanshow’s new generation HiLPC. With HiLPC innovative system architecture, the communication speed of the ESL is greatly improved, and the update speed can reach over 60,000 pieces/hour/ESL controller, making it quicker and easier to install and bind. The super-high system throughput of the HiLPC enables updating tens of millions of devices within a few minutes, which brings clients a totally novel experience of real-time ESL services and enhances clients’ capability of managing globally distributed stores.
With this upgraded protocol, Hanshow ESL Solution enables batch, timed, and synchronized task updates in the same store with errors controlled at the millisecond level, and it can also synchronize dynamic price changes, realize precise timing synchronization while online and even offline, and track the position of products, greatly improving the operational efficiency of stores.
The new generation HiLPC makes it possible to nomadically update ESLs, which opens opportunities for new industrial applications. It also supports flashing light prompts for any number of goods being selected to help employees quickly find the location of goods for sorting. It supports dynamic network resource allocation used in conjunction with Wi-Fi, solving the network incompatibility challenges. In addition, the new generation protocol combined with ESL controllers and financial-grade security chips provides the most reliable data protection available.
Breaking through with smarter and better performance
Hanshow also unveiled the four-color ESL product series that supports black, white, red, and yellow color displays in any combination, expanding the digital display possibilities for retailers. This product’s screen updating and flashing speeds are significantly optimized compared with previous models, especially in conjunction with the new generation HiLPC.
In addition to the breakthrough in vivid displays, Hanshow has focused on increasing its precision applications for specific industry demands. Hanshow’s thermal detector and DIY ESL solutions are designed to help retailers solve special applications for temperature monitoring and automatic temperature change alerts, as well as the product use adaptation problems of home improvement retail and other business forms.
For years, Hanshow has pursued continuous innovation based on customer needs and remained committed to enabling customers to achieve upgrading for better operational efficiency. The new generation HiLPC and four-color ESL directly achieve this by drastically reducing the energy supply and paper materials needed to operate a physical store. In the future, Hanshow will continue developing innovative digital technology, fully assist customers in digital upgrading, and create a green, leading, and sustainable digital new experience in the industry.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
